Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study.

The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
Istvan BitterYulia Dyachkova

Abstract

The aim of this study was to compare patients' preference for olanzapine orodispersible tablet (ODT) with oral conventional tablet (OCT). A 12-week randomized, crossover, multinational, open-label study was conducted to estimate the proportion of patients preferring ODT or OCT. Outpatients with stable schizophrenia on OCT monotherapy were randomly assigned 1:1 to ODT or OCT. Compliance and drug attitude were measured using the Drug Attitude Inventory (DAI-10) and Medication Adherence Form (MAF) scales; tolerability and safety by Association for Methodology and Documentation in Psychiatry (AMDP-5) questionnaire and adverse event summary. A total of 175 patients answered a preference question: 106 (61%) preferred ODT and 48 (27%) preferred OCT (P<0.001 adjusted for treatment sequence); 21 (12%) expressed no preference. There was no significant change in DAI-10 with either formulation. MAF was above 75% in 94% vs. 93% of patients on ODC and OCT, respectively. Compliance as measured by tablet count was above 98% on both formulations. The adverse event profiles did not differ between formulations. Mean weight increase over 6 weeks on ODT was 0.8 kg and on OCT was 0.6 kg. Given the importance of patients' preference for treatment pla...Continue Reading

References

Apr 1, 1986·The British Journal of Psychiatry : the Journal of Mental Science·D Bobon, B Woggon
Jun 30, 1994·The New England Journal of Medicine·J P Kassirer
Apr 3, 2001·BMJ : British Medical Journal·C ChilversUNKNOWN Counselling versus Antidepressants in Primary Care Study Group
Feb 13, 2002·The Journal of Clinical Psychiatry·Alex HoferW Wolfgang Fleischhacker
Jul 15, 2003·Human Psychopharmacology·Hervé AllainJean-Marc Gandon
Aug 2, 2003·The International Journal of Neuropsychopharmacology·Bruce J KinonSara Kollack-Walker
Oct 20, 2004·The Journal of Clinical Psychiatry·Oliver FreudenreichDonald C Goff
May 17, 2005·Patient Education and Counseling·Kristina H JahngM Robin DiMatteo
Aug 9, 2005·Current Medical Research and Opinion·Andrew J Dowson, Per Almqvist
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Feb 10, 2006·Acta Psychiatrica Scandinavica·A O AdewuyaA B Eegunranti
Apr 4, 2006·The British Journal of Psychiatry : the Journal of Mental Science·Louise Howard, Graham Thornicroft
Aug 11, 2007·International Clinical Psychopharmacology·Stephan HeresFrank-Gerald Pajonk
Sep 22, 2007·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Istvan BitterGabor S Ungvari
Oct 9, 2007·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Richard L Street
Mar 14, 2008·Human Psychopharmacology·Jamie KaragianisBharat Chawla
Jun 28, 2008·Journal of Psychopharmacology·M X PatelA David
Sep 20, 2008·CNS Neuroscience & Therapeutics·Luis SanInmaculada Gilaberte
Nov 4, 2008·BMJ : British Medical Journal·UNKNOWN Preference Collaborative Review Group

❮ Previous
Next ❯

Citations

Feb 22, 2012·Patient Preference and Adherence·William MontgomeryGavan Harrison
Apr 26, 2014·PloS One·Maarten BakMarjan Drukker
Oct 17, 2015·Drug Development and Industrial Pharmacy·Hemlata G PatilKamalinder K Singh
Nov 29, 2011·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ichiro KusumiTsukasa Koyama
Mar 5, 2015·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Marta Slavkova, Jörg Breitkreutz
May 11, 2017·Pharmaceutical Development and Technology·Hesham M TawfeekGhareb M Soliman
Jul 8, 2017·CNS Spectrums·Andrew J Cutler, Gregory W Mattingly
Aug 8, 2020·Expert Review of Pharmacoeconomics & Outcomes Research·Ziyi Lin, Jianwei Xuan
Jan 18, 2020·Pharmaceutics·Enrica MendittoIsabel F Almeida

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here